Dimensional Fund Advisors LP Takes Position in Insmed Incorporated (NASDAQ:INSM)

Dimensional Fund Advisors LP bought a new stake in Insmed Incorporated (NASDAQ:INSM) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 12,089 shares of the biopharmaceutical company’s stock, valued at approximately $810,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Insmed by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock valued at $393,636,000 after purchasing an additional 383,714 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Insmed by 15.2% in the 2nd quarter. Principal Financial Group Inc. now owns 1,657,760 shares of the biopharmaceutical company’s stock valued at $111,069,000 after purchasing an additional 218,480 shares in the last quarter. Capital International Investors acquired a new stake in shares of Insmed in the 1st quarter valued at $43,973,000. Hood River Capital Management LLC boosted its stake in shares of Insmed by 6.3% in the 1st quarter. Hood River Capital Management LLC now owns 962,501 shares of the biopharmaceutical company’s stock valued at $26,113,000 after purchasing an additional 56,682 shares in the last quarter. Finally, Clearbridge Investments LLC acquired a new position in Insmed during the 1st quarter worth about $25,242,000.

Insider Buying and Selling

In related news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $74.35, for a total value of $2,072,208.85. Following the sale, the insider now directly owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 78,882 shares of company stock valued at $5,765,446. 4.60% of the stock is owned by corporate insiders.

Insmed Stock Performance

Shares of INSM stock opened at $74.56 on Monday. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The stock has a market cap of $11.08 billion, a PE ratio of -14.26 and a beta of 1.11. The stock has a 50-day moving average of $73.84 and a 200-day moving average of $56.80. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to the consensus estimate of $87.95 million. Insmed’s revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.78) earnings per share. As a group, sell-side analysts expect that Insmed Incorporated will post -5.41 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on INSM shares. StockNews.com downgraded shares of Insmed from a “hold” rating to a “sell” rating in a research report on Friday, August 9th. Evercore ISI upped their price target on shares of Insmed from $42.00 to $75.00 and gave the stock an “outperform” rating in a research report on Friday, June 21st. Morgan Stanley upped their price target on shares of Insmed from $60.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 12th. Truist Financial upped their price target on shares of Insmed from $85.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday. Finally, The Goldman Sachs Group upped their price target on shares of Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.73.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.